Yuya Hirasawa

Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors

Kiyohiro Ando, Kazuyuki Hamada, Makoto Watanabe et al. · Anticancer Research · 2019 · 62 citations · Full text

Medicine, Oncology, Pharmacology +17

Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor

Kazuyuki Hamada, Junya Isobe, Kouya Hattori et al. · Frontiers in Immunology · 2023 · 48 citations · Full text

Life Sciences, Microbiology, Oncology +16

Antibiotic Usage Reduced Overall Survival by over 70% in Non-small Cell Lung Cancer Patients on Anti-PD-1 Immunotherapy

Kazuyuki Hamada, Kiyoshi Yoshimura, Yuya Hirasawa et al. · Anticancer Research · 2021 · 44 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody

Masakazu Murayama, Masahiro Hosonuma, Atsuo Kuramasu et al. · Scientific Reports · 2024 · 36 citations · Full text

Medicine, Immunology, Oncology +17

Increased Plasma Soluble PD-1 Concentration Correlates with Disease Progression in Patients with Cancer Treated with Anti-PD-1 Antibodies

Ryotaro Ohkuma, Katsuaki Ieguchi, Makoto Watanabe et al. · Biomedicines · 2021 · 35 citations · Full text

Medicine, Oncology, Pharmacology +17